Full Press Release Details
LOS ANGELES, May 26, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (Nasdaq:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that it will be participating in two upcoming investor conferences in June. Linda Marb n, Ph.D., Chief Executive Officer of Capricor will provide a company overview and update on its clinical development programs.
Jefferies 2015 Healthcare Conference, June 1, 2015, 10:30 a.m. EDT, in New York City; a webcast of this presentation will be available on Capricor's website at http://capricor.com/news/events/
The JMP Securities Life Sciences Conference, June 23, 2015, 12:00 p.m. EDT, in New York City
About Capricor Therapeutics
Capricor Therapeutics, Inc. (Nasdaq:CAPR) is a clinical-stage biotechnology company with expertise in the field of cardiovascular disease aiming to develop novel therapies for diseases with significant unmet medical needs. Our lead programs target post myocardial infarction (heart attack), heart failure and Duchenne Muscular Dystrophy. The Company has two leading product candidates under investigation: Cenderitide, a natriuretic peptide receptor agonist, and CAP-1002, a cardiac cell therapy. Cenderitide is in development for the outpatient treatment of heart failure as well as potential other indications. CAP-1002 is in development for the treatment of post myocardial infarction (heart attack), advanced heart failure and Duchenne muscular dystrophy associated cardiomyopathy. In addition, the Company is conducting research and development on its exosomes platform technology for cardiac diseases and other potential indications. For additional information visit www.capricor.com.